Page results
-
This page provides information about the Palliative care and symptom control team
-
EMIS outage caused backlog of result messages via Keystone
-
The UCLH immunotherapy-neurotoxicity multidisciplinary service (IO-neurotox MDT) was established collaboratively between the National Hospital for Neurology and Neurosurgery (NHNN) and a nationwide oncology clinical team to offer high-quality diagnostic and management guidance on the care of cancer patients with, or suspected of having, any form of neurological complication of immunotherapy (immune-checkpoint inhibitor therapy). We provide multidisciplinary care for patients who are referred from their GP or from other hospitals. Although immune-related neurotoxicity is relatively rare it may be severe and is associated with significant disability and high risk to patients if not recognised and managed promptly and well.
-
A team of clinician scientists at UCLH have identified the factors which predict full hearing recovery, with the strongest predictor being treatment with steroids within seven days of a sudden drop in hearing.
-
Outcome of National Institute for Health and Care Excellence (NICE) Technology Appraisal for Exagamglogene autotemcel (Exa-cel) for treating transfusion- dependent beta thalassaemia [ID4015] in individuals 12 years and over.
-
Pfizer Limited, in agreement with the Medicines Healthcare products Regulatory Agency (MHRA), has withdrawn the product, while a review of the benefits and risks is carried out.
-
This page describes a surgical keyhole procedure to remove fibroids, called a laparoscopic myomectomy.
-
To mark International Brain Tumour Awareness Week, UCLH and The National Brain Appeal are announcing a new clinical trial for patients with recurrent glioblastoma brain cancer.
-
This page has been written for parents of children who have been diagnosed with congenital cytomegalovirus (cCMV) infection.
-
The diagnostic haematology clinics at UCLH perform comprehensive blood testing, including blood film examination, immunophenotyping and molecular testing.
File results
-
FOI/2024/0694 - Off-framework agency shifts/ spend/ contact details January-August 2024
-
FOI/2024/0702 - Community respiratory service mapping/ community-based bronchiectasis services
-
FOI/2024/0703 - Neurofibromatosis type 1 treatment/ volume of medication dispensed
-
FOI/2024/0704 - Contingencies to support visitors/ patients/ contractors witnessing a distressing event
-
FOI/2024/0716 - Toxicological screening/ testing/ training and information to patients
-
FOI/2024/0718 - Mental health/ electronic health records software/ dermatology screening/ imaging services/ medical devices for wound care
-
FOI/2024/0721 - New biologic and targeted medications/ treatment within dermatology
-
FOI/2024/0727 - Clinical photography solution contract/ spend
-
FOI/2024/0740 - A&E tooth decay admissions for 2021/22, 2022/23 and 2023/24
-
FOI/2024/0741 - HR, finance and payroll contracts/ software updates/ staff contact details